Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 72


Confounding factors of ultrafiltration and protein analysis in extracellular vesicle research.

Vergauwen G, Dhondt B, Van Deun J, De Smedt E, Berx G, Timmerman E, Gevaert K, Miinalainen I, Cocquyt V, Braems G, Van den Broecke R, Denys H, De Wever O, Hendrix A.

Sci Rep. 2017 Jun 2;7(1):2704. doi: 10.1038/s41598-017-02599-y.


Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.

Lambein K, Van Bockstal M, Vandemaele L, Van den Broecke R, Cocquyt V, Geenen S, Denys H, Libbrecht L.

Virchows Arch. 2017 Nov;471(5):575-587. doi: 10.1007/s00428-017-2161-8. Epub 2017 May 31.


Secretome analysis of breast cancer-associated adipose tissue to identify paracrine regulators of breast cancer growth.

Lapeire L, Hendrix A, Lecoutere E, Van Bockstal M, Vandesompele J, Maynard D, Braems G, Van Den Broecke R, Müller C, Bracke M, Cocquyt V, Denys H, De Wever O.

Oncotarget. 2017 Jul 18;8(29):47239-47249. doi: 10.18632/oncotarget.17592.


The isolation of morphologically intact and biologically active extracellular vesicles from the secretome of cancer-associated adipose tissue.

Jeurissen S, Vergauwen G, Van Deun J, Lapeire L, Depoorter V, Miinalainen I, Sormunen R, Van den Broecke R, Braems G, Cocquyt V, Denys H, Hendrix A.

Cell Adh Migr. 2017 Mar 4;11(2):196-204. doi: 10.1080/19336918.2017.1279784. Epub 2017 Feb 1.


Systematic review: The oncological safety of adipose fat transfer after breast cancer surgery.

Waked K, Colle J, Doornaert M, Cocquyt V, Blondeel P.

Breast. 2017 Feb;31:128-136. doi: 10.1016/j.breast.2016.11.001. Epub 2016 Nov 10. Review.


Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer.

De Jaeghere E, Vandecasteele K, Claes K, Makar A, Tummers P, Cocquyt V, Denys H.

Acta Clin Belg. 2017 Feb;72(1):6-11. doi: 10.1080/17843286.2016.1188455. Epub 2016 May 31. Review.


When fat becomes an ally of the enemy: adipose tissue as collaborator in human breast cancer.

Lapeire L, Denys H, Cocquyt V, De Wever O.

Horm Mol Biol Clin Investig. 2015 Jul;23(1):21-38. doi: 10.1515/hmbci-2015-0018. Review.


Resection of single metachronous liver metastases from breast cancer stage I-II yield excellent overall and disease-free survival. Single center experience and review of the literature.

Vertriest C, Berardi G, Tomassini F, Vanden Broucke R, Depypere H, Cocquyt V, Denys H, Van Belle S, Troisi RI.

Dig Surg. 2015;32(1):52-9. doi: 10.1159/000375132. Epub 2015 Feb 11. Review.


Differential regulation of extracellular matrix protein expression in carcinoma-associated fibroblasts by TGF-β1 regulates cancer cell spreading but not adhesion.

Van Bockstal M, Lambein K, Van Gele M, De Vlieghere E, Limame R, Braems G, Van den Broecke R, Cocquyt V, Denys H, Bracke M, Libbrecht L, De Wever O.

Oncoscience. 2014 Oct 15;1(10):634-48. eCollection 2014.


The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling.

Van Deun J, Mestdagh P, Sormunen R, Cocquyt V, Vermaelen K, Vandesompele J, Bracke M, De Wever O, Hendrix A.

J Extracell Vesicles. 2014 Sep 18;3. doi: 10.3402/jev.v3.24858. eCollection 2014.


Stable metabolic disease on FDG-PET provides information on response to endocrine therapy for breast cancer.

Kruse V, VAN DE Wiele C, Maes A, Borms M, Pottel H, VAN Belle S, Cocquyt V.

Q J Nucl Med Mol Imaging. 2017 Mar;61(1):108-114. doi: 10.23736/S1824-4785.16.02727-8. Epub 2014 Oct 7.


Cancer-associated adipose tissue promotes breast cancer progression by paracrine oncostatin M and Jak/STAT3 signaling.

Lapeire L, Hendrix A, Lambein K, Van Bockstal M, Braems G, Van Den Broecke R, Limame R, Mestdagh P, Vandesompele J, Vanhove C, Maynard D, Lehuédé C, Muller C, Valet P, Gespach CP, Bracke M, Cocquyt V, Denys H, De Wever O.

Cancer Res. 2014 Dec 1;74(23):6806-19. doi: 10.1158/0008-5472.CAN-14-0160. Epub 2014 Sep 24.


CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence. Factors influencing the area under the ROC curve.

Kruse V, Van de Wiele C, Borms M, Maes A, Pottel H, Sathekge M, Cocquyt V.

Nuklearmedizin. 2014 Aug 6;53(4):131-8. doi: 10.3413/Nukmed-0634-13-12.


Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype.

Van Bockstal M, Lambein K, Denys H, Braems G, Nuyts A, Van den Broecke R, Cocquyt V, De Wever O, Libbrecht L.

Virchows Arch. 2014 Sep;465(3):275-89. doi: 10.1007/s00428-014-1609-3. Epub 2014 Jun 29.


Reproducibility of FDG PET based metabolic tumor volume measurements and of their FDG distribution within.

Kruse V, Mees G, Maes A, D'Asseler Y, Borms M, Cocquyt V, Van De Wiele C.

Q J Nucl Med Mol Imaging. 2015 Dec;59(4):462-8. Epub 2014 Apr 3.


Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports.

Marlier J, Cocquyt V, Brochez L, Van Belle S, Kruse V.

Endocrine. 2014 Dec;47(3):878-83. doi: 10.1007/s12020-014-0199-9. Epub 2014 Feb 21.


Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Zhao C, Chia YL, Hoch U, Hannah AL, Perez EA; NKTR-102 Study Group.

Lancet Oncol. 2013 Nov;14(12):1216-25. doi: 10.1016/S1470-2045(13)70429-7. Epub 2013 Oct 4.


Imaging requirements for personalized medicine: the oncologists point of view.

Kruse V, Belle SV, Cocquyt V.

Curr Pharm Des. 2014;20(14):2234-49. Review.


Cancer risk in immune-mediated inflammatory diseases (IMID).

Beyaert R, Beaugerie L, Van Assche G, Brochez L, Renauld JC, Viguier M, Cocquyt V, Jerusalem G, Machiels JP, Prenen H, Masson P, Louis E, De Keyser F.

Mol Cancer. 2013 Aug 29;12(1):98. doi: 10.1186/1476-4598-12-98. Review.


Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast.

Van Bockstal M, Lambein K, Gevaert O, De Wever O, Praet M, Cocquyt V, Van den Broecke R, Braems G, Denys H, Libbrecht L.

Histopathology. 2013 Oct;63(4):520-33. doi: 10.1111/his.12188. Epub 2013 Jul 26.


Supplemental Content

Loading ...
Support Center